During the last session, Lineage Cell Therapeutics Inc (AMEX:LCTX)’s traded shares were 0.8 million, with the beta value of the company hitting 1.27. The 52-week high for the LCTX share is $1.61, that puts it down -133.33 from that peak though still a striking 30.43% gain since the share price plummeted to a 52-week low of $0.48. The company’s market capitalization is $153.17M, and the average intraday trading volume over the past 10 days was 1.42 million shares, and the average trade volume was 2.70 million shares over the past three months.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Lineage Cell Therapeutics Inc (LCTX) registered a 1.45% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.45% in intraday trading to $0.69, hitting a weekly high. The stock’s 5-day price performance is 3.69%, and it has moved by 19.98% in 30 days. Based on these gigs, the overall price performance for the year is -31.87%. The short interest in Lineage Cell Therapeutics Inc (AMEX:LCTX) is 21.3 million shares and it means that shorts have 8.84 day(s) to cover.
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -7.73% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.62M as predicted by 6 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 1.36M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.12M and 1.44M respectively. In this case, analysts expect current quarter sales to shrink by -23.46% and then drop by -5.75% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 19.25%. While earnings are projected to return 8.33% in 2025, the next five years will return 9.14% per annum.
LCTX Dividends
Lineage Cell Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
Lineage Cell Therapeutics Inc insiders own 0.56% of total outstanding shares while institutional holders control 50.49%, with the float percentage being 50.78%. BROADWOOD CAPITAL INC is the largest shareholder of the company, while 151.0 institutions own stock in it. As of 2024-06-30, the company held over 41.67 million shares (or 22.7798% of all shares), a total value of $41.55 million in shares.
The next largest institutional holding, with 9.56 million shares, is of BLACKROCK INC.’s that is approximately 5.2264% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $9.53 million.
Also, the Mutual Funds coming in first place with the largest holdings of Lineage Cell Therapeutics Inc (LCTX) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 4.42 shares. This amounts to just over 2.00 percent of the company’s overall shares, with a $3.07 million market value. The same data shows that the other fund manager holds slightly less at 4.0, or about 1.81% of the stock, which is worth about $2.78 million.
